<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00593294</url>
  </required_header>
  <id_info>
    <org_study_id>2007-12-2871</org_study_id>
    <secondary_id>CE209/07</secondary_id>
    <nct_id>NCT00593294</nct_id>
  </id_info>
  <brief_title>Oral Contraceptive and Cardiovascular Risk in PCOS</brief_title>
  <official_title>Comparison of Oral Contraceptive Versus Physical Exercise Effects on Cardiovascular and Metabolic Risk Factors in PCOS Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federico II University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oral contraceptive therapy is routinely used for the treatment of menstrual disturbances of&#xD;
      patients with polycystic ovary syndrome (PCOS).&#xD;
&#xD;
      To date, the cardiovascular risk (CVR) of the oral contraceptives (OC) are known but no data&#xD;
      are available on the CVR in PCOS patients treated with OC or physical exercise.&#xD;
&#xD;
      The purpose of this study is to compare the effects of OC to physical exercise on the CVR of&#xD;
      PCOS women and show the hormonal and metabolic effects of these two different treatment.&#xD;
&#xD;
      We hypothesize that physical exercise has the same beneficial effects of OC therapy on&#xD;
      hormonal and metabolic features of PCOS women with less cardiovascular consequences.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One hundred and fifty PCOS women will be enrolled. The diagnosis of PCOS was made based&#xD;
      according to the Rotterdam criteria (1). Specifically, patients with anovulation and clinical&#xD;
      and/or biochemical hyperandrogenism were enrolled.&#xD;
&#xD;
      Patients will be randomly allocated in three groups (OC, physical exercise and placebo group)&#xD;
      using a computer-software. Fifty PCOS patients will be treated with OC (Drospirenone 3 mg,&#xD;
      Ethynylestradiol 30 microgram = Yasmin, Schering, Milan,Italy) other fifty PCOS will be&#xD;
      undergone physical exercise, whereas other fifty will be treated with placebo tablets (one&#xD;
      tablet once daily; placebo group). The duration of the treatment will be 6 months.&#xD;
&#xD;
      Patients treated with OC will be instructed to follow their usual diet and physical activity,&#xD;
      whereas patients undergone to physical exercise will be instructed to follow a detailed&#xD;
      regular physical training program and for the diet they will be advised for the quality of&#xD;
      food to eat. All subjects will be nonsmokers and none will drink alcoholic beverages.&#xD;
&#xD;
      Each subject will undergo follow-up visits under (at three and 6 months from treatment&#xD;
      starting) and after treatment (at three and 6 months from treatment withdrawal). At each&#xD;
      follow-up visit, in all subjects the same operator will perform clinical, hormonal, metabolic&#xD;
      and cardiovascular assessments by carotid and brachial artery US&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Outcomes: Intima media thickness by carotid ultrasonography (US) and Flow Mediated Dilation by brachial artery US</measure>
    <time_frame>Basal and after 3 and 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcomes: Clinical, hormonal, and metabolic assessments</measure>
    <time_frame>Basal and after 3 and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>A,1,I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B, 2, II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C,3,III</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Physical exercise</intervention_name>
    <description>45 minutes each day for three times/week for 6 months</description>
    <arm_group_label>A,1,I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OC - Drospirenone plus Ethynylestradiol</intervention_name>
    <description>1 cp for 21 days each month for 6 months of OC (Drospirenone 3 mg plus Ethynylestradiol 30 microgram = Yasmin, Schering, Milan, Italy)</description>
    <arm_group_label>B, 2, II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin, polyvitamins tablets</intervention_name>
    <description>Tablet of vitamin 1cp for 21 days each month for 6 months</description>
    <arm_group_label>C,3,III</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Polycystic ovary syndrome&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 or &gt;40 years&#xD;
&#xD;
          -  BMI higher than 30 and lower than 18&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Hypothyroidism, hyperprolactinemia, Cushing's syndrome, nonclassical congenital&#xD;
             adrenal hyperplasia, use of OC, glucocorticoids, antiandrogens, ovulation induction&#xD;
             agents, antidiabetic or antiobesity drugs or other hormonal drugs within the previous&#xD;
             6 months&#xD;
&#xD;
          -  Subjects with neoplastic, metabolic (including glucose intolerance), hepatic, and&#xD;
             cardiovascular disorder or other concurrent medical illness (i.e. diabetes, renal&#xD;
             disease, or malabsorptive disorders, cephalea)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Orio, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Molecular and Clinical Endocrinology and Oncology University Federico II Naples Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gaetano Lombardi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Molecular and Clinical Endocrinology and Oncology University Federico II Naples Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefano Palomba, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Chair of Obstetrics and Gynecology, University &quot;Magna Graecia&quot; Catanzaro, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Molecular and Clinical Endocrinology and Oncology, University &quot;Federico II&quot;</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004 Jan;81(1):19-25.</citation>
    <PMID>14711538</PMID>
  </reference>
  <verification_date>December 2007</verification_date>
  <study_first_submitted>January 4, 2008</study_first_submitted>
  <study_first_submitted_qc>January 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2008</study_first_posted>
  <last_update_submitted>January 14, 2008</last_update_submitted>
  <last_update_submitted_qc>January 14, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2008</last_update_posted>
  <responsible_party>
    <name_title>Francesco Orio</name_title>
    <organization>Dpt of Mol and Clin Endocrinology and Oncology Federico II University of Naples</organization>
  </responsible_party>
  <keyword>PCOS</keyword>
  <keyword>oral contraceptives</keyword>
  <keyword>physical exercise</keyword>
  <keyword>CVR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drospirenone</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

